USA | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from USA totalled $ 49 billion in 2023. Sales of commodity group 3002 from USA went up by 15.5% compared to 2022: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 6.7 billion (cumulative exports of commodity group 3002 from USA amounted $43 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 2.47% of total exports from USA (cumulative merchandise exports from USA totalled $ 2.01 trillion in 2023). The share of commodity group 3002 in total exports from USA increased by 0.377 p.p. compared to 2022 (it was 2.09% in 2022 and cumulative exports from USA were equal to $ 2.06 trillion).
Exports of commodity group 3002 amounted to 55% of total sales of group "" from USA in 2023 (the value of exports of commodity group from USA amounted to $90 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from USA increased by 3.52 p.p. compared to 2022 (it was 51% in 2022, and exports of commodity group from USA were $83 billion).
Where does USA export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from USA in 2023:
- Netherlands with a share of 11.7% (5.85 billion US$)
- Belgium with a share of 11.1% (5.58 billion US$)
- China with a share of 10.8% (5.41 billion US$)
- Germany with a share of 10.2% (5.1 billion US$)
- Ireland with a share of 5.81% (2.89 billion US$)
- Japan with a share of 5.41% (2.7 billion US$)
- Austria with a share of 4.39% (2.19 billion US$)
- Canada with a share of 4.3% (2.14 billion US$)
- Switzerland with a share of 4.05% (2.02 billion US$)
- United Kingdom with a share of 3.21% (1.6 billion US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from USA in 2023 represented by the following main commodity groups:
- 2.65% (1.32 billion US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to USA totalled $ 81 billion in 2023. Sales of commodity group 3002 to USA went up by 26% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 17.1 billion (the value of imports of commodity group 3002 to USA was equal to $64 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 2.58% of total import flow to USA (in 2023, total imports to USA amounted to $ 3.16 trillion). The share of commodity group 3002 in total imports to USA increased by 0.665 p.p. compared to 2022 (it was 1.92% in 2022 and cumulative imports to USA were equal to $ 3.37 trillion).
Imports of commodity group 3002 reached 46% of total imports of group "" to USA in 2023 (imports of commodity group to USA totalled $177 billion in 2023). The share of purchases of commodity group 3002 in total imports of commodity group to USA increased by 6.81 p.p. compared to 2022 (it was 39% in 2022, and imports of commodity group to USA accounted for $164 billion).
Where does USA import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of USA in 2023:
- Ireland with a share of 27% (22 billion US$)
- Germany with a share of 14.3% (11.7 billion US$)
- Netherlands with a share of 11.4% (9.38 billion US$)
- Singapore with a share of 7.54% (6.18 billion US$)
- Switzerland with a share of 6.13% (5.03 billion US$)
- Belgium with a share of 6.03% (4.94 billion US$)
- Japan with a share of 4.17% (3.41 billion US$)
- United Kingdom with a share of 3.96% (3.25 billion US$)
- Korea with a share of 3.06% (2.5 billion US$)
- Austria with a share of 3.02% (2.48 billion US$)
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to USA in 2023 represented by the following main commodity groups:
- 1.05% (867 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
